Expanded access programs (EAPs) provide medication to patients with life-threatening, treatment-refractory illnesses before regulatory approval and allow the acquisition of safety information. A 2-part, multisite EAP to evaluate abacavir, a carbocyclic nucleoside reverse-transcriptase inhibitor for use in combination antiretroviral therapy, was conducted. The EAP involved 113,000 adults infected with human immunodeficiency virus type 1 (HIV-1) who no longer responded to commercially available treatment regimens. Part A (openlabel trials) examined the efficacy, safety, and tolerance of abacavir, and part B (provision of abacavir through expanded access) assessed only the occurrence of serious adverse events. By month 2 of abacavir-containing treatment, plasma HIV-1 RNA levels decreased by у0.5 log 10 in 31.4% of patients, and 5.6% of the patients had HIV-1 RNA levels decrease to !400 copies/mL. Drug-related serious adverse events were reported by 7.7% of patients, the most common of which were nausea, skin rash, diarrhea, malaise or fatigue, and fever. Approximately 4.6% of patients experienced a hypersensitivity reaction that was possibly drug related. Overall, the types and incidences of adverse events reported in the abacavir EAP were similar to those reported in phase 2 and 3 clinical trials evaluating abacavir.
PATIENTS AND METHODS

Patients.
Part A of the abacavir EAP began in 1997 with strict inclusion criteria and monitoring of all adverse events, whether drug related or not. Male and female patients were eligible for enrollment in part A if they were 113 years of age (or, in some countries, 118 years of age, in accordance with local regulatory requirements); were HIV-1 seropositive, as confirmed by ELISA and Western blot test; had a plasma HIV-1 RNA level of 130,000 copies/mL and CD4 ϩ cell count of !100 cells/mm 3 ; had infections that showed evidence of failure to respond to treatment while the patients were receiving standard antiretroviral therapy (at least 2 NRTIs and 1 protease inhibitor [PI] ); had a history of intolerance to у2 different NRTI-PI regimens; and were not participating in or would not qualify for a controlled clinical trial of abacavir.
After a review of safety data collected in part A, part B was initiated in 1998 and used less stringent eligibility criteria than did part A. Part B required only that HIV-infected patients had infections that did not respond to standard therapy and that the patients' doctors were unable to construct a viable treatment regimen without abacavir. There were no plasma HIV-1 RNA or CD4 ϩ cell count criteria for inclusion into part B. Only serious adverse events were reported, whether drug related or not, and no data on efficacy were collected. Patients were ineligible for both parts A and B of the study if they were pregnant or breast feeding; if they had a documented hypersensitivity reaction to abacavir; if they used alcohol or illicit drugs; if they had renal failure that required dialysis; if they had hepatic failure, as evidenced by hyperbilirubinemia of grade 3 or 4 and aspartate aminotransaminase levels 15 times the upper limit of normal; or if they had a serious medical condition (e.g., diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction). Patients were allowed to take erythropoietin, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or some combination of these, concurrently during the EAP.
Study design. The abacavir EAP was international, multicenter, nonrandomized, and open-label in design. It was conducted at 68 sites in the United States, 11 in Canada, and 58 in Europe and Australia. The EAP protocol was reviewed and approved by the institutional review boards at each study site. Informed consent was obtained from all participating patients before study procedures began. Study conduct conformed to human experimentation guidelines of the Declaration of Helsinki and Title 21, Parts 50 and 56, of the United States Code of Federal Regulations. At European, Canadian, and Australian sites, the study was performed under local regulatory requirements.
In part A, data regarding demographic characteristics and all adverse events were recorded for all patients. In addition, plasma HIV-1 RNA and CD4 ϩ cell count data were obtained from the first 200 patients at baseline, month 1, and month 2.
Patients were seen in the clinic at a preentry visit (baseline; day 1) and at week 2 (only the first 200 patients in the United States), month 1, month 2, and every 2 months thereafter for up to 20 months. Plasma HIV-1 RNA levels were measured by use of the Roche Amplicor PCR assay (Roche; lower limit of detection, 400 copies/mL). Additional laboratory studies were performed at the discretion of the investigator. In part B, patients were seen in the clinic at a preentry visit (baseline) and at months 1 and 3, and every 3 months thereafter, until the end of participation or termination of the program. As in part A, abacavir was included as a component in a treatment regimen that contained у1 other antiretroviral drug that the patient had not received in the past. Antiretroviral drugs obtained through other EAPs were allowed. Only serious adverse events were noted, including all data on all hypersensitivity reactions, regardless of severity. Evaluations of plasma HIV-1 RNA were not collected, although these may have been determined by the investigator.
Patients were to continue receiving abacavir until a treatmentlimiting adverse event was experienced. Women were to discontinue abacavir therapy if they became pregnant. Although it was not required, patients were encouraged to discontinue abacavir therapy if there was no evidence of clinical benefit (HIV-1 RNA reduction or CD4 ϩ cell count elevation) or if the disease progressed (as evidenced by the appearance of a new Centers for Disease Control and Prevention class C AIDS-defining event). Development of a clinical syndrome compatible with a hypersensitivity reaction to abacavir was an absolute requirement for immediate discontinuation and a contraindication to restarting abacavir. Patients could also withdraw permanently from either part A or B of the abacavir EAP at their or their doctors' discretion or if the patient was lost to follow-up. Treatment. Abacavir therapy was given at a dosage of 300 mg twice daily, which was supplied as Ziagen (Glaxo Wellcome) in combination with other antiretroviral agents. It was strongly advised that the investigators include у1 agent that the patient had not received in the past.
Assessment of efficacy. Efficacy (part A only) was assessed by change in log 10 HIV-1 RNA levels between baseline and month 2; number and percentage of patients achieving reduction in log 10 HIV-1 RNA of either у0.5 copies/mL or у1.0 copies/mL; and number and percentage of patients achieving HIV-1 RNA plasma levels of !400 copies/mL (defined as "undetectable"). Comparisons of efficacy were made according to the type of regimen patients received at baseline (no antiretroviral agent; 1 antiretroviral agent; 11 NRTI; 1 NRTI plus 1 nonnucleoside reverse-transcriptase inhibitor [NNRTI] ; an NRTI plus a PI; an NNRTI plus a PI; an NRTI plus an NNRTI plus a PI; or other).
Assessment of safety. Safety was assessed by recording nonserious adverse events in part A only and serious adverse events, hypersensitivity reactions, and laboratory value changes in patients who had made у1 visit after baseline in parts A and B. For part A, an "adverse event" was considered any unintended sign, symptom, or disease temporally associated with the use of the study drug, even if it was not drug related. A "nonserious adverse event" included an exacerbation or increase in frequency of a preexisting condition or illness, or a condition detected after the administration of the drug. A "serious adverse event" was defined as a fatal or life-threatening event, a disabling or incapacitating event, cancer, and any event requiring hospitalization. A congenital anomaly in the offspring of a patient who received the drug was also considered a serious adverse event, as were abnormalities in the findings of laboratory screenings for toxicity related to hematology, serum chemistry, and urinalysis.
Hypersensitivity reaction to abacavir. At the start of this study, only 7 cases of hypersensitivity reaction to abacavir had been reported to the manufacturer; thus, available data on this clinical syndrome were limited. Consequently, the clinical definition of hypersensitivity reaction to abacavir evolved. In part A, a "possible hypersensitivity reaction to abacavir" was retrospectively defined by the occurrence of fever accompanied by nausea, rash, malaise, or vomiting within the first 6 weeks after starting treatment. In part B, the definition broadened to a constellation of symptoms that indicated multiorgan or body system involvement. In addition, all hypersensitivity reactions to abacavir were defined as "serious adverse events," regardless of the severity of any of the symptoms.
In part A, cases of hypersensitivity reaction to abacavir were identified by means of a symptom-based computer algorithm to estimate the frequency of hypersensitivity reaction cases. To be termed a hypersensitivity reaction by this algorithm, у2 of the following events had to have occurred within 2 days of each other: fever, rash, or any gastrointestinal complaint (nausea, vomiting, diarrhea, or abdominal pain). Patients were also included if the report from the investigator applied the terms "hypersensitivity reaction," "drug reaction," or "allergic reaction" to any patient who permanently discontinued study medication within 14 days of the onset of an adverse event. Additional details, such as those regarding individual symptoms, may not have been reported in these cases.
Statistical analysis. In part A, summary statistics for the efficacy analysis were presented for log 10 plasma HIV-1 RNA levels. Values that were less than the detection limit of 400 copies/mL were assigned a numerical value of 399 copies/mL. Adverse events and serious adverse events were summarized by frequency of occurrence, regardless of whether they were caused by abacavir, another medication taken by the patient, or a complication of HIV-1 infection. Deaths were summarized by cause (HIV disease progression or other).
RESULTS
Patient characteristics and disposition.
The demographic characteristics of patients who participated in parts A and B were similar (table 1) . Of the 2580 patients in part A, 1837 (71%) were white, 2316 (90%) were men, and mean age was 40 years. Study sites in the United States and Canada included more black patients and fewer women than did sites in Europe and Australia (respective percentage of black patients, 18% vs. 4%; respective percentage of women, 9% vs. 14%). At baseline, the median HIV-1 RNA plasma level was 5.4 log 10 copies/mL, and the median CD4 ϩ cell count was 30.2 cells/mm 3 , reflecting the advanced HIV-1 disease of the patients. Seventy-two percent of patients in part A had a history of у1 previous AIDSdefining opportunistic illnesses, the most common of which were Pneumocystis carinii pneumonia (31%), esophageal candidiasis (19%), wasting syndrome (16%), Mycobacterium avium complex infection (13%), and cytomegalovirus retinitis (10%).
Part B enrolled 11,624 patients from March through December 1998, with a peak enrollment rate of 310 patients per week. Two hundred thirty patients had participated in part A; 11,038 (95%) of 11,624 patients enrolled in part B had у1 reported follow-up visit and were included in the safety analysis. Demographic profiles of patients in part B were similar to those of part A. No data regarding virus load, CD4 ϩ cell count, or history of opportunistic illness were obtained. Efficacy of combination therapy. By month 1 or 2 after the initiation of abacavir-containing treatment, 31.4% of patients had a у0.5-log 10 reduction in HIV-1 RNA level and 19% had a у1-log 10 reduction, with 5.6% of patients achieving HIV-1 RNA levels of !400 copies/mL. A better virologic outcome was achieved in patients who added 1 or 2 new antiretroviral agents to their regimens (compared with patients for whom no new drugs were added). HIV-1 RNA levels decreased by a mean of 0.8 log 10 copies/mL in patients who received 2 new antiretroviral agents (in addition to abacavir), but they decreased only by a mean of 0.5 log 10 copies/mL in patients receiving no or just 1 new agent ( figure 1 ). The number of NRTIs that a NOTE. Data are no. of patients (% of patients participating in the labeled part of the study), unless otherwise indicated. The total number of patients listed within each baseline characteristic does not necessarily equal the number of patients enrolled as a result of missing data points.
patient had received before initiation of abacavir did not influence virologic response (data not shown).
Although no statistical comparisons were attempted, more patients appeared to achieve HIV-1 RNA levels of !400 copies/ mL and a у1 log 10 reduction in HIV-1 RNA level if they had 2 PIs added to their abacavir-containing regimen by treatment month 1 (11.8% and 20.8%, respectively) or if they had been NNRTI naive and had efavirenz added to their regimen by treatment month 1 (10.7% and 36.9%, respectively). Rates for HIV-1 RNA levels of !400 copies/mL or a у1 log 10 reduction in HIV-1 RNA at the same time point were 4.6% and 19.5%, respectively, for patients with previous exposure to all 4 NRTIs available at the time of the study (lamivudine, zidovudine, stavudine, and didanosine). Patients who had у2 new antiretroviral drugs added to abacavir treatment at the start of the study had month-1 response rates of 6.8% and 26.9% (!400 copies/ mL and у1 log 10 reduction, respectively). Those patients who added adefovir had month-1 response rates of 0.9% and 24.8%, whereas those who were NNRTI experienced at screening and began therapy with efavirenz had response rates of 5.6% and 26.1% (!400 copies/mL and у1 log 10 reduction, respectively).
Adverse events. Nonserious adverse events were reported by 1809 (71.6%) of the 2527 patients from whom these safety data were available. Nonserious adverse events considered by investigators to be possibly related to abacavir were reported by 1079 (42.7%) of this safety subset. The 5 most common abacavir-related adverse events were nausea (in 308 patients [12 3 ). Of the 11,038 patients for whom data regarding serious adverse events were assessable, serious adverse events in general were reported by 1612 patients (14.6%) and abacavir-related serious adverse events were reported by 848 patients (7.7%). The 5 most common abacavir-related serious adverse events One hundred thirty (5.1%) of the 2527 safety-assessable patients in part A were identified by the algorithm to have experienced symptoms suggesting a hypersensitivity reaction to abacavir. The symptoms most commonly seen as part of this reaction were, in decreasing order of frequency, fever, rash, nausea, diarrhea, malaise and fatigue, nausea with vomiting, and headache. The symptoms in 29 (22.3%) of these 130 patients were reported by health care providers to be "allergy" or "allergic reaction."
In part B, investigators diagnosed 404 cases (4.6%) of hypersensitivity reaction among 8841 subjects with у1 recorded follow-up visit. In most cases, this adverse event resolved without sequelae within 1 week after patients discontinued abacavir.
Deaths. Two hundred seventy (2.3%) of all patients enrolled in the EAP died during the study. Approximately twothirds of these deaths were due to HIV disease progression (176 patients [65%]). Eighty-five deaths (31%) were due to other causes, the most common of which were sepsis with associated renal failure, pneumonia, and cardiac arrest. Twenty-seven deaths were considered to be possibly related to study treatment. Cause of death in these patients included liver failure (in 6 patients, 2 of whom had concurrent renal failure), pancreatitis (in 5), cardiovascular events (in 4), respiratory failure (in 3), hypersensitivity reaction (in 2), renal failure (in 1), and other causes (in 6; infection, sudden death, or HIV-related cerebral infarction). Nine patients died of unknown causes.
DISCUSSION
The results of the abacavir EAP indicate that the spectrum and frequency of adverse events experienced by this population were similar to those reported among the patients enrolled in controlled clinical trials. This is despite the advanced state of HIV-1 infection and the greater variety of concomitant medications taken by the EAP participants, as compared with patients in controlled clinical trials. Overall, no new safety concerns were identified through the EAP.
The ability to attribute any given adverse event to an antiretroviral drug provided in an EAP is limited. Most patients added у1 other drug concurrent with the addition of abacavir. For example, peripheral neuropathy, which was not identified as a side effect of abacavir in controlled clinical trials, was reported among 2.3% of the EAP population. A significant proportion of the EAP participants, however, also received agents known to cause peripheral neuropathy: stavudine (31.1% of patients), didanosine (21.9%), or zalcitabine (2.9%) [13] . Stevens-Johnson syndrome was reported as a drug-related adverse event in 10 patients in the abacavir EAP, all of whom received у1 agent known to cause Stevens-Johnson syndrome; in the majority of cases, the agent was an NNRTI [14] . By using the estimate that 25% of patients in the EAP received nevirapine along with abacavir, and by knowing that the expected rate of Stevens-Johnson syndrome for nevirapine is 0.3% [14] , we would have expected there to be ∼8 cases of Stevens-Johnson syndrome caused by this NNRTI. Thus, no increase in the frequency of this severe reaction was seen in the abacavir EAP.
Other concurrently administered drugs, as well as the advanced nature of HIV disease in participants in the abacavir EAP, also may have predisposed patients to additional adverse events [13] . Although additional adverse events might be expected once abacavir therapy was initiated, the results of the EAP showed that this is not always the case. The safety profile seen in the abacavir EAP was similar to that described elsewhere [2] for patients receiving abacavir as part of a first-time HAART regimen for the treatment of less-advanced HIV infection. The 4.6% overall incidence of the hypersensitivity reaction noted in part B of the abacavir EAP fell within the range reported in controlled clinical trials in HIV-infected patients [15, 16] . Thus, the highly advanced degree of HIV disease and the extensive prior use of other antiretroviral therapy drugs characteristic of the abacavir EAP population did not appear to increase the incidence of the hypersensitivity reaction. Since the abacavir EAP, further evidence has accumulated suggesting that the degree of experience that patients have had with antiretroviral treatment does not increase the risk of hypersensitivity reaction. Indeed, a preliminary analysis of 12400 cases showed that the incidence of the hypersensitivity reaction in patients treated with HAART regimens that contain abacavir was significantly lower in antiretroviral-experienced patients than it was in antiretroviral-naive patients [15] . The incidence of the hypersensitivity reaction in part A did not differ notably from that in part B (5.1% vs. 4.6%, respectively) despite differences in the definition, reporting requirements, and analysis of cases. The case definition was broader in part B and the reporting more complete. The method of identifying cases by algorithm in part A was imprecise in that false-positive cases may have been included and false-negative cases excluded. Hypersensitivity reactions in EAP participants usually resolved without sequelae within a week after abacavir was discontinued, as is consistent with the resolution pattern reported elsewhere [15] . Rare cases of fatal hypersensitivity reaction occurred at an estimated rate of 2-4 cases per 10,000 patients treated with abacavir. With additional information and better understanding of this syndrome now available, careful attention to early signs and symptoms should further reduce the rate.
In the abacavir EAP, the percentage of patients achieving HIV-1 RNA plasma levels of !400 copies/mL within 2 months of the initiation of abacavir therapy was 5.6%. This was much lower than that reported at this time point in other clinical trials of antiretroviral-experienced patients who began therapy with abacavir [10, 17] . The relatively poor virologic response in the abacavir EAP population could be due to several factors. The likelihood of plasma HIV-1 RNA levels decreasing to !400 copies/mL depends on the baseline levels; in the EAP program, the levels were relatively high. CD4 ϩ cell count may also be inversely correlated with the level of therapeutic success, and again, patients in the EAP had very low initial CD4 ϩ cell counts.
Finally, in view of the extensive treatment histories, patients in the EAP may have harbored viral isolates with multidrug resistance. Although the resistance profile of abacavir was not well described before initiation of the EAP, subsequent studies show a reduced response in patients for whom the viral genotype demonstrates у3 mutations in the HIV-1 RT gene [1] . The design of the abacavir EAP shared many of the features of EAPs for other antiretroviral agents reported elsewhere [18] [19] [20] [21] [22] [23] . Consistent with the definition of an EAP, this program included patients with a life-threatening disease (HIV infection) and a paucity of therapeutic alternatives. Although EAPs have been initiated after enrollment in phase 3 trials has been completed [12] , the abacavir EAP was initiated soon after phase 1/ 2 efficacy or safety data were available, and it was conducted in parallel with the controlled phase 3 trials. The population evaluated in the abacavir EAP was comparable in size to that evaluated in the stavudine EAP (112,000 persons) [23] , larger than that in the zalcitabine European EAP (517 persons) [22] , and smaller than that in the didanosine EAP (127,000 persons) [23] . Low baseline CD4
ϩ cell count was a requirement of other
EAPs [21] , as it was for part A of the abacavir EAP. However, persons with less-advanced disease and the potential to add other new antiretroviral agents to their therapies were considered more likely to benefit from having early access to abacavir therapy. Thus, a specific limit on CD4 ϩ cell count was not an inclusion criterion, and the inclusion of other investigational agents in the patients' treatment was permitted. The goal of the program was to reach patients before all treatment options had been exhausted (i.e., before the development of high-level multidrug viral resistance). In summary, the abacavir EAP studied 113,000 patients with advanced, treatment-refractory HIV disease, and it showed that abacavir is generally well tolerated and that the types and incidences of adverse events were similar to those reported in phase 2/3 clinical trials that have evaluated abacavir and abacavir-containing HAART. Virologic responses observed in this program were limited because of the severity of HIV disease at baseline and the degree of previous antiretroviral treatment that likely led to high-level multidrug resistance among the viral isolates among patients in the EAP. Because of the nature of HIV disease, similar EAPs can be expected to be conducted for novel antiretroviral agents whose safety and efficacy profiles are not fully defined at the program's initiation. Efforts should be directed toward developing methods to better predict response, thereby offering the greatest possibility of clinical benefit while limiting exposure to medications for which little safety information is available.
